Agoracom Blog Home

Archive for the ‘Empower Clinics Inc.’ Category

VIDEOS: Empower Clinics: Q&A with Steven McAuley | Answering Investor Questions | April 29, 2024

Posted by Paul Nanuwa at 12:15 PM on Tuesday, April 30th, 2024

Welcome to Empower Clinics’ Q&A series, where Steven McAuley personally addresses investor questions. He dives deep into Empower Clinics’ latest developments and future plans, providing valuable insights for potential investors. Don’t miss the chance to learn more about our company firsthand, and stay tuned for more enlightening discussions! Watch all episodes below.

PART 1

PART 2

PART 2, Cont’d

PART 3

PART 4

 

 

Empower Clinics Emerges: Unveiling Significant Growth and a Visionary Strategy to Reinvigorate Investor Confidence

Posted by Paul Nanuwa at 3:12 PM on Thursday, April 11th, 2024

As the clinical trials market propels towards an estimated value of USD 887.0 Billion by 2032, Empower Clinics stands at the forefront of harnessing these burgeoning opportunities. Amidst the industry’s dynamic landscape, Empower Clinics is strategically positioned to leverage its expertise and drive innovation in medical research and patient-centric initiatives.

Industry Outlook and Empower Clinics’ Trajectory

The clinical trials industry is witnessing unprecedented growth fueled by escalating demand for innovative therapies and treatments. Empower Clinics is poised to navigate this trajectory with precision, capitalizing on emerging trends and technological advancements to drive transformative change. As the industry evolves, Empower Clinics remains steadfast in its commitment to advancing medical research and delivering impactful solutions.

Voices of Authority

Industry leaders echo Empower Clinics’ strategic vision, recognizing the company’s pivotal role in shaping the future of clinical trials. With a focus on collaboration and innovation, Empower Clinics is poised to drive meaningful advancements that enhance patient outcomes and revolutionize healthcare delivery.

Empower Clinics’ FLASH Highlights

Empower Clinics is a healthcare company with a growing research and clinical trials division that is currently achieving early success in the Dallas and Los Angeles markets. It has already been awarded its first clinical trial from a Global Fortune 500 Pharmaceutical Company and the company has grown their active sites from 2 in the fall to 6 at present. Principal Investigators have increased from 6 to 14 with an active pipeline in motion.  That foundation of doctors and medical offices opens the door to potential major contract wins from pharmaceutical companies that need speed and smarts from partners like Empower to get their clinical trials completed.

Real-world Relevance

Empower Clinics’ impact extends beyond the laboratory, translating into tangible benefits for patients and stakeholders alike. By championing patient-centric approaches and leveraging advanced technologies, Empower Clinics is at the forefront of delivering transformative healthcare solutions that address pressing medical challenges.

Looking Ahead with Empower Clinics

As the clinical trials industry continues to evolve, Empower Clinics remains focused on its mission to drive innovation and improve patient outcomes. With a forward-thinking approach and a dedication to excellence, Empower Clinics is poised to unlock new opportunities and redefine the future of medical research and patient care.

Conclusion

In a landscape defined by unprecedented growth and innovation, Empower Clinics emerges as a leader in the clinical trials arena. As the industry continues to evolve, Empower Clinics stands ready to lead the charge towards a brighter, more innovative future.

YOUR NEXT STEPS

Visit $EPW HUB On AGORACOM: https://agoracom.com/ir/EmpowerClinics
Visit $EPW 5 Minute Research Profile On AGORACOM: https://agoracom.com/ir/EmpowerClinics/profile
Visit $EPW Official Verified Discussion Forum On AGORACOM: https://agoracom.com/ir/EmpowerClinics/forums/discussion

DISCLAIMER AND DISCLOSURE

This record is published on behalf of the featured company or companies mentioned (Collectively “Clients”), which are paid clients of Agora Internet Relations Corp or AGORACOM Investor Relations Corp. (Collectively “AGORACOM”)

AGORACOM.com is a platform. AGORACOM is an online marketing agency that is compensated by public companies to provide online marketing, branding and awareness through Advertising in the form of content on AGORACOM.com, its related websites (smallcapepicenter.com; smallcappodcast.com; smallcapagora.com) and all of their social media sites (Collectively “AGORACOM Network”) .  As such please assume any of the companies mentioned above have paid for the creation, publication and dissemination of this article / post.

You understand that AGORACOM receives either monetary or securities compensation for our services, including creating, publishing and distributing content on behalf of Clients, which includes but is not limited to articles, press releases, videos, interview transcripts, industry bulletins, reports, GIFs, JPEGs, (Collectively “Records”) and other records by or on behalf of clients. Although AGORACOM compensation is not tied to the sale or appreciation of any securities, we stand to benefit from any volume or stock appreciation of our Clients.  In exchange for publishing services rendered by AGORACOM on behalf of Clients, AGORACOM receives annual cash and/or securities compensation of typically up to $125,000.

Facts relied upon by AGORACOM are generally provided by clients or gathered by AGORACOM from other public sources including press releases, SEDAR and/or EDGAR filings, website, powerpoint presentations.  These facts may be in error and if so, Records created by AGORACOM may be materially different. In our video interviews or video content, opinions are those of our guests or interviewees and do not necessarily reflect the opinion of AGORACOM.

From time to time, reference may be made in our marketing materials to prior Records we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

NO INVESTMENT ADVICE

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell products or securities.

You understand and agree that no content in this record or published by AGORACOM constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person and that no such content is tailored to any specific person’s needs. We will never advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

Neither the writer of this record nor AGORACOM is an investment advisor.  Both are neither licensed to provide nor are making any buy or sell recommendations. For more information about this or any other company, please review their public documents to conduct your own due diligence.

If you have any questions, please direct them to [email protected]

For our full website disclaimer, please visit https://agoracom.com/terms-and-conditions

 

Empower Clinics Emerges from Stealth Mode: A Game-Changer in Healthcare Innovation

Posted by Paul Nanuwa at 3:49 PM on Monday, April 8th, 2024

Small Cap Clinical Trial Company Sets Stage for Significant Growth

Empower Clinics, a burgeoning force in the healthcare sector, has stepped out of regulatory-mandated stealth mode with a robust growth trajectory and an ambitious plan to restore shareholder value. Led by CEO Steven McAuley, the company is poised for substantial expansion in its research and clinical trials division, marking a pivotal moment in its journey towards industry prominence.

Unveiling the Vision

Empower Clinics is not just another player in the healthcare landscape; it’s a company with a grand vision and a strategic roadmap to revolutionize clinical trials. As it emerges from stealth mode, Empower brings to the forefront a compelling narrative of growth and innovation. With a focus on research and clinical trials, the company has swiftly garnered attention for its early successes in key markets such as Dallas and Los Angeles including already being awarded its first clinical trial from a Global Fortune 500 Pharmaceutical Company.

Foundational Growth and Promising Prospects

Under McAuley’s leadership, Empower has made significant strides in expanding its operational footprint. From just two active sites in the fall, the company has scaled up to six active sites today. Moreover, the number of Principal Investigators has more than doubled, from six to fourteen. This exponential growth not only underscores Empower’s commitment to excellence but also sets the stage for potential contract wins from global pharmaceutical giants.

Seizing Opportunities in a Booming Market

Empower Clinics’ timing couldn’t be more opportune. With the global Clinical Trials Market projected to reach USD 92.45 billion by 2030, fueled by the burgeoning pharmaceutical, biotechnology, and medical device sectors, Empower is primed to capitalize on this burgeoning market. As demographics shift and medical research advances, the company stands at the forefront of innovation, poised to play a pivotal role in shaping the future of healthcare.

Insightful Interview: A Glimpse into Empower’s Strategy

In a compelling interview with AGORACOM, CEO Steven McAuley provided invaluable insights into Empower’s growth trajectory and strategic imperatives. From navigating regulatory challenges to positioning the company for sustainable growth, McAuley’s vision and leadership shine through, offering shareholders and investors a glimpse into the company’s promising future.

Empower Clinics: A Signal of Hope in Healthcare Innovation

As Empower Clinics emerges from stealth mode, it ushers in a new era of innovation and growth in the healthcare sector. With a steadfast commitment to excellence, a robust foundation of operational success, and a visionary leadership team at the helm, the company is well-positioned to unlock tremendous value for shareholders and stakeholders alike.

Conclusion: Charting a Path to Success

Empower Clinics’ journey from stealth mode to growth mode signifies a significant milestone in its evolution as a player in the healthcare industry. With a compelling business model, a strategic focus on research and clinical trials, and a deep commitment to driving shareholder value, Empower is poised to redefine the future of healthcare innovation. As investors and stakeholders alike rally behind the company’s vision, the future looks brighter than ever for Empower Clinics and its pioneering approach to healthcare transformation.

YOUR NEXT STEPS

Visit $EPW HUB On AGORACOM: https://agoracom.com/ir/EmpowerClinics
Visit $EPW 5 Minute Research Profile On AGORACOM: https://agoracom.com/ir/EmpowerClinics/profile
Visit $EPW Official Verified Discussion Forum On AGORACOM: https://agoracom.com/ir/EmpowerClinics/forums/discussion

DISCLAIMER AND DISCLOSURE

This record is published on behalf of the featured company or companies mentioned (Collectively “Clients”), which are paid clients of Agora Internet Relations Corp or AGORACOM Investor Relations Corp. (Collectively “AGORACOM”)

AGORACOM.com is a platform. AGORACOM is an online marketing agency that is compensated by public companies to provide online marketing, branding and awareness through Advertising in the form of content on AGORACOM.com, its related websites (smallcapepicenter.com; smallcappodcast.com; smallcapagora.com) and all of their social media sites (Collectively “AGORACOM Network”) .  As such please assume any of the companies mentioned above have paid for the creation, publication and dissemination of this article / post.

You understand that AGORACOM receives either monetary or securities compensation for our services, including creating, publishing and distributing content on behalf of Clients, which includes but is not limited to articles, press releases, videos, interview transcripts, industry bulletins, reports, GIFs, JPEGs, (Collectively “Records”) and other records by or on behalf of clients. Although AGORACOM compensation is not tied to the sale or appreciation of any securities, we stand to benefit from any volume or stock appreciation of our Clients.  In exchange for publishing services rendered by AGORACOM on behalf of Clients, AGORACOM receives annual cash and/or securities compensation of typically up to $125,000.

Facts relied upon by AGORACOM are generally provided by clients or gathered by AGORACOM from other public sources including press releases, SEDAR and/or EDGAR filings, website, powerpoint presentations.  These facts may be in error and if so, Records created by AGORACOM may be materially different. In our video interviews or video content, opinions are those of our guests or interviewees and do not necessarily reflect the opinion of AGORACOM.

From time to time, reference may be made in our marketing materials to prior Records we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

NO INVESTMENT ADVICE

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell products or securities.

You understand and agree that no content in this record or published by AGORACOM constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person and that no such content is tailored to any specific person’s needs. We will never advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

Neither the writer of this record nor AGORACOM is an investment advisor.  Both are neither licensed to provide nor are making any buy or sell recommendations. For more information about this or any other company, please review their public documents to conduct your own due diligence.

If you have any questions, please direct them to [email protected]

For our full website disclaimer, please visit https://agoracom.com/terms-and-conditions

VIDEO – Empower Clinics Comes Out Of Stealth Mode With Big Growth And A Grand Plan To Restore Shareholder Value

Posted by Paul Nanuwa at 6:46 PM on Friday, April 5th, 2024

Empower Clinics is a healthcare company with a growing research and clinical trials division that is currently achieving early success in the Dallas and Los Angeles markets, including already being awarded its first clinical trial from a Global Fortune 500 Pharmaceutical Company.

But Empower is just getting started according to CEO Steven McAuley, who has come out of regulator mandated stealth mode to report very promising business growth to shareholders.

Specifically, while under cease trade, Empower has grown their active sites from 2 in the fall to 6 today – and Principal Investigators from 6 to 14 today.  That foundation of doctors and medical offices opens the door to potential major contract wins from pharmaceutical companies that need speed and smarts from partners like Empower to get their clinical trials completed.

Empower’s timing couldn’t be better because Fortune Business Insights states the global Clinical Trials Market size is projected to reach USD 92.45 billion in 2030, driven by expanding pharmaceutical, biotechnology, and medical device R&D pipelines as developed G20 nations demographics get increasingly older.  This positions Empower to play a pivotal role  in this transformative era of healthcare.

Watch this powerful interview with CEO Steven McAuley and AGORACOM Founder George Tsiolis.

EMPOWER CLINICS ANNOUNCES AWARD OF FIRST CLINICAL TRIAL FROM GLOBAL FORTUNE 500 PHARMACEUTICAL COMPANY

Posted by Aidi Munoz at 9:40 AM on Tuesday, September 26th, 2023

Empower Clinics Inc (EPW: CSE) (EPWCF: PINK), a leading healthcare company, is proud to announce a significant milestone in its research and clinical trials division. Its subsidiary, EPW Curesearch LLC (“EPWC”), has successfully secured its inaugural clinical trial from a major European pharmaceutical powerhouse with a staggering market capitalization exceeding $100 billion. This monumental achievement is set to impact the future of healthcare outcomes worldwide.

Building upon its previous announcement on July 31, 2023, which highlighted multiple study applications covering diverse disease states, Empower Clinics confirms that this awarded clinical trial will be dedicated to addressing Chronic Obstructive Pulmonary Disease (COPD). The trial will be spearheaded by one of the company’s most seasoned Principal Investigators (PIs).

The collaboration between Empower Clinics, their PI, and the pharmaceutical sponsor is poised to enroll between 20 to 35 patients, primarily from the existing patient roster, with the recruitment window extending into mid-2024 and the possibility of extensions. Remarkably, there are no restrictions on the maximum number of patients per site, enabling EPWC to source additional participants from external medical centers, hospitals, and various social recruitment channels, including Facebook, Instagram, Twitter, and other digital marketing avenues.

Steven McAuley, Chairman & CEO of Empower Clinics, expressed his enthusiasm, stating, “We are all ecstatic to receive our first awarded clinical trial, a result of consistent and persistent effort over the past number of months. Our focus on partnering with large established medical centers and very experienced medical doctors has proven successful.” He further anticipates additional sponsor due diligence, site visits, and awards in the future.

Empower Clinics has strategically aligned itself with practicing medical doctors, who are specialists in their respective fields and have previous research and clinical trials experience. These PIs play a pivotal role in the success of Empower’s Site Management Organization (SMO), facilitating meaningful revenues from the Biotech and Pharmaceutical industries, providing oversight and support to patients, and acting as a crucial liaison between pharmaceutical companies and Contract Research Organizations (CROs).

While the company continues to navigate through a Cease Trade Order and accounting and audit procedures, the enormous market opportunity beckons. The Clinical Research Organization (CRO) Services Market is set to reach $127.3 billion by 2028, driven by the ever-expanding pharmaceutical, biotechnology, and medical device R&D pipelines, as well as advancements in clinical trial processes. Empower Clinics is positioned to play a pivotal role in this transformative era of healthcare.

About Empower:

Empower is a patient-focused healthcare company committed to making a positive impact on lives and future healthcare outcomes through clinical trials. With two clinical research sites and six principal investigators, Empower operates as a Site Management Organization (SMO) with multiple clinical trials in the pipeline. Additionally, the company has announced its intention to create a healthcare AI spinout focused on enhancing patient identification, recruitment, and onboarding for clinical trials.

Read release: https://www.einpresswire.com/article/657704521/empower-clinics-announces-award-of-first-clinical-trial-from-global-fortune-500-pharmaceutical-company

VIDEO – Empower Clinics Proposes Spin Out As Growth Of Research and Clinical Trials Accelerates With Multiple Clinical Study Applications

Posted by Aidi Munoz at 4:55 PM on Thursday, August 3rd, 2023

Empower Clinics Proposes Spin Out As Growth Of Research and Clinical Trials Accelerates With Multiple Clinical Study Applications From Pharmaceutical Companies.

In a recent press release, Empower Clinics Inc. (CSE: EPW) (OTC: EPWCF) announced its proposal for a division spin-out and a strategic move towards the healthcare artificial intelligence (AI) sector. After a thorough strategic review, the company intends to complete a direct spin-out of its wholly-owned subsidiary, “Subco,” and simultaneously acquire a healthcare AI technology or service company.

In this exclusive interview, Steven McAuley, Chairman & CEO of Empower Clinics, expressed his enthusiasm about this strategic move. He highlighted that this spin-out and focus on healthcare AI as a separate entity would unlock significant shareholder value and provide clarity to investors regarding each company’s direction.

Regarding the Target, McAuley discussed the potential impact of AI and machine learning in the healthcare sector, particularly in patient recruitment for clinical trials. Empower’s expertise in research and clinical trials uniquely positions them to understand the significance of AI in drug development. By applying AI algorithms to patient rosters and data, the industry can significantly improve patient recruitment speed, accuracy, and overall success rates in new drug development.

Overall, this strategic move by Empower Clinics marks a promising step into the fast-growing healthcare AI sector and represents an exciting opportunity for shareholders and investors alike. As developments unfold, investors are encouraged to stay informed about the company’s progress in this transformative endeavor.

Now sit back relax and watch this powerful interview with Steven McAuley, Chairman & CEO of Empower Clinics.

VIDEO – Empower Clinics CERES Initiative Full Steam Ahead To Manage 1.2M Passengers 2022. More Chess Moves Reveal US Clinic and NASDAQ Goals

Posted by AGORACOM-JC at 11:42 AM on Tuesday, February 22nd, 2022
Epw logo1

Empower Clinics CEO Steve McAuley took questions from shareholders and provided a powerful update on the following topics:

  • Partnership With CERES Terminals Canada. Scope of Work & Revenue Mode
  • Status Of Clinics Acquisitions – Imminent Closin
  • Appointment Of Healthcare Powerhouse Anthony Tomasello To The Board
    • What His Appointment Means For US Expansion and NASDAQ Goal
  • Appointment Of Carolyn Shields As SVP Of Clinics Operations
    • What Her Appointment Means For Clinics Expansion In 202
  • New Clinic Openings – Next Ribbon Cutting Soon With Steve Attending For Shareholder “Town Hall” Meeting

As always we want to thank shareholders for taking the time to submit great questions.

VIDEO – Empower Clinics Q3-21 Revenue Up 372% YOY, Further Clinic Expansion Under Way

Posted by AGORACOM-JC at 4:37 PM on Monday, November 29th, 2021

Nine-month year-over-year revenue growth of 1,349% 

Empower Clinics continues to fire on all cylinders. This is evident by the strong Q3 results that the company released last week. 

Steven McAuley, Chairman and CEO of Empower commented: 

“This quarter marked the start of a new chapter for the Company and the Empower team. We launched The Medi-Collective brand and clinics, expanded Kai Labs’ facilities and completed the acquisition of MediSure. Each of these milestones is an intrinsic aspect of our strategic growth vision. 

Key Q3-2021 Highlights

  • Revenue from continuing operations of $405,707 compared to $85,960 in Q3 2020, representing 372% year-over-year growth.
  • Revenue from continuing operations of $3,226,335 for nine months YTD 2021 compared to $222,690 for nine months YTD 2020, representing 1,349% year over year growth.

What does CEO Steven McAuley think of these results?

“With positive year-over-year growth coming out of this quarter, we will maximize our fully operational divisions’ capabilities and reach across Canada and the U.S. I’m encouraged by our partnerships and acquisitions progress into Q4 2021 and look forward to the coming months.”

Sit back, relax and watch this powerful interview.

VIDEO – With First New Clinic Launches In Ontario Imminent, Empower Clinics Is Sitting On A Launchpad That Will Keep The Company Flying Through 2022 And Beyond

Posted by AGORACOM-JC at 4:04 PM on Monday, August 16th, 2021

In an interview just over a month ago, Empower Clinics CEO Steve McAuley talked about how the Company is in full-blown growth mode that were best summarized as follows:

“Multiple opportunities have been percolating and I’m going to turn up the heat”

To this added seeing 

“substantially higher market cap” for the Company, as well as, growth that will be “deserving of an uplist”.

Today McAuley and the team at Empower backed up those words with this announcement:

“The Company can now confirm the first new clinic launches will take place in September – location and ribbon cutting ceremonies to be announced – with rollouts of further locations continuing on a regular basis from that point forward.”

In today’s interview McAuley takes shareholders through a detailed overview of the foundation that has now been built, ready to launch and strong enough to catapult Empower into a completely new orbit.
Watch this great interview.  Welcome to the launch pad.   

VIDEO – With 2020 Audit Complete, Empower Clinics CEO Steve McAuley Sees Big Growth For Operations, US Expansion, Market Cap & Uplisting

Posted by AGORACOM-JC at 6:17 PM on Monday, July 5th, 2021

With $US 3.2M in 2020 revenue, representing a 58% increase over the previous year, you would think Empower Clinics CEO Steve McAuley would use his first interview after the filing to celebrate. 

He isn’t. 

Rather, with Fiscal 2020 having come to end more than 6 months ago, the 2020 results are a distant rear view mirror shot of a Company that is in full-blown growth mode and can be best summarized as follows: 

“Multiple opportunities have been percolating and I’m going to turn up the heat” 

To this end McAuley sees a “substantially higher market cap” for the Company, as well as, growth that will be “deserving of an uplist”. 

We could try to list all the powerful things he had to say in this interview – but best we let you watch/hear it straight from Steve in this amazing interview.